Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
31.18
-0.86 (-2.67%)
At close: Nov 12, 2025, 4:00 PM EST
31.10
-0.07 (-0.24%)
Pre-market: Nov 13, 2025, 8:19 AM EST
Legend Biotech Stock Forecast
Stock Price Forecast
The 11 analysts that cover Legend Biotech stock have a consensus rating of "Strong Buy" and an average price target of $70.82, which forecasts a 127.17% increase in the stock price over the next year. The lowest target is $54 and the highest is $84.
Price Target: $70.82 (+127.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 6 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 11 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $60 | Strong Buy | Maintains | $75 → $60 | +92.46% | Oct 17, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $78 → $76 | Buy | Maintains | $78 → $76 | +143.79% | Oct 9, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $55 → $66 | Buy | Initiates | $55 → $66 | +111.71% | Aug 27, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $77 → $78 | Buy | Maintains | $77 → $78 | +150.20% | Aug 25, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $75 → $77 | Buy | Maintains | $75 → $77 | +146.99% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
1.06B
from 627.24M
Increased by 68.68%
Revenue Next Year
1.57B
from 1.06B
Increased by 48.49%
EPS This Year
-1.01
from -0.97
EPS Next Year
0.46
from -1.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2B | 1.8B | |||
| Avg | 1.1B | 1.6B | |||
| Low | 927.1M | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 87.6% | 73.9% | |||
| Avg | 68.7% | 48.5% | |||
| Low | 47.8% | 27.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.79 | 0.93 | |||
| Avg | -1.01 | 0.46 | |||
| Low | -1.43 | 0.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.